DA
ARCT icon

Denali Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Denali Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,200
Closed -$209K – 197
2024
Q1 		$209K Buy
+6,200
New +$220K 0.06% 222

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Denali Advisors's ARCT Position: Q2 2024 in Review

Denali Advisors sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 6,200 shares — an estimated $209K sold.

Denali Advisors first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $209K in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Denali Advisors reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Denali Advisors sold 6,200 Arcturus Therapeutics shares in Q2 2024, an estimated $209K.
  • Denali Advisors first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Denali Advisors's Arcturus Therapeutics position peaked at $209K in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Denali Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.